Stock HLUN B H. LUNDBECK A/S
Add to a list
To use this feature you must be a member
Log inSign up

H. Lundbeck A/S Stock

Equities

HLUN B

DK0061804770

Pharmaceuticals

Market Closed - Nasdaq Copenhagen
Other stock markets
 11:20:00 2024-11-29 am EST 		5-day change 1st Jan Change
44.00 DKK +0.09% Intraday chart for H. Lundbeck A/S -2.83% +34.31%
Nov. 28 Lundbeck's acquisition conditions for Longboard have been met, closing the deal on December 2 FW
Nov. 28 H. Lundbeck Closes Tender Offer for Longboard Pharmaceuticals Acquisition MT
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last hours
Enjoy this offer
* See conditions on site

Valuation: H. Lundbeck A/S

Capitalization 42.1B 5.96B 5.65B 5.25B 4.69B 8.35B 504B 9.15B 65.05B 24.22B 207B 22.38B 21.89B 897B P/E ratio 2024 *
14.1x
P/E ratio 2025 * 12.1x
Enterprise value 48.43B 6.85B 6.5B 6.04B 5.39B 9.6B 580B 10.52B 74.83B 27.86B 238B 25.75B 25.18B 1,031B EV / Sales 2024 *
2.2x
EV / Sales 2025 * 1.91x
Free-Float
30.74%
Yield 2024 *
2.11%
Yield 2025 * 2.42%
More valuation ratios * Estimated data

Chart: H. Lundbeck A/S

Dynamic Chart

Latest news: H. Lundbeck A/S

Lundbeck's acquisition conditions for Longboard have been met, closing the deal on December 2 Nov. 28 FW
H. Lundbeck Closes Tender Offer for Longboard Pharmaceuticals Acquisition Nov. 28 MT
H. Lundbeck Launches Late-stage Trial of Multiple System Atrophy Drug Nov. 27 MT
Lundbeck initiates Phase 3 study of amlenetug in multiple system atrophy Nov. 27 FW
H. Lundbeck Initiates a Phase III Trial with Amlenetug for the Treatment of Multiple System Atrophy Nov. 27 CI
H. Lundbeck A/S : Lundbeck: possible rebound given outlook Nov. 20Our Logo
Trump-induced Pharma fears shouldn't be long-lived Nov. 19Alphavalue
Danske Bank raises target price for Lundbeck to DKK 50 (49), reiterates 'Hold' - BN Nov. 14 FW
H LUNDBECK : Q3 exceeded expectations; lower end of the guidance upgraded Nov. 13Alphavalue
H. Lundbeck A/S, Q3 2024 Earnings Call, Nov 13, 2024 Nov. 13
Better than expected from Lundbeck - raises lower end of forecasts (update) Nov. 13 FW
Better than expected from Lundbeck Nov. 13 FW
H. Lundbeck A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 13 CI
More news

Last Transcript: H. Lundbeck A/S

Logo H. Lundbeck A/S
H. Lundbeck A/S, Q3 2024 Earnings Call, Nov 13, 2024
Nov. 13
More transcripts

Analysts' recommendations: H. Lundbeck A/S

Danske Bank raises target price for Lundbeck to DKK 50 (49), reiterates 'Hold' - BN Nov. 14 FW
H LUNDBECK : Q3 exceeded expectations; lower end of the guidance upgraded Nov. 13Alphavalue
Lundbeck expected to report DKK 1,581 million in adjusted ebitda - First Call Nov. 11 FW
SEB raises target price for Lundbeck to DKK 47 (45), reiterates hold - BN Nov. 01 FW
Jefferies raises target price for Lundbeck to DKK 50 (35), reiterates Hold Oct. 30 FW
More recommendations

Press Releases: H. Lundbeck A/S

Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled Nov. 28 AQ
Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy Nov. 27 AQ
H Lundbeck A/S : Transcript (Lundbeck Transcript Get Visual 2024 11 13 1300 CET) Nov. 14 PU
H Lundbeck A/S : Investor Presentation (Lundbeck InvesterDeck 9M2024 FINAL) Nov. 13 PU
H Lundbeck A/S : Release (Q3 2024 Corporate Release FINAL) Nov. 13 PU
More press releases

News in other languages: H. Lundbeck A/S

H. Lundbeck A/S: Wende in Sicht? Nov. 22
H. Lundbeck A/S: mogelijk herstel gezien de vooruitzichten Nov. 21
Lundbeck: possibile rimbalzo in base alle prospettive Nov. 20
Lundbeck: posible rebote fruto de las perspectivas Nov. 20
Lundbeck : possible rebond compte tenu des perspectives Nov. 19
More news

Quotes and Performance

1 day+0.09%
1 week-2.83%
1 month-1.48%
3 months-8.18%
6 months+16.59%
Current year+34.31%
More quotes

Course Extremes

1 week
43.44
Extreme 43.44
45.46
1 month
42.50
Extreme 42.5
46.92
Current year
31.62
Extreme 31.62
49.38
1 year
31.62
Extreme 31.62
49.38
3 years
23.30
Extreme 23.295
49.38
5 years
23.30
Extreme 23.295
49.38
10 years
23.30
Extreme 23.295
49.38
More quotes

Managers and Directors: H. Lundbeck A/S

Director TitleAgeSince
Charl van Zyl CEO
 Chief Executive Officer 57 2023-09-30
Jörg Hornstein DFI
 Director of Finance/CFO 47 2022-08-31
Tarek Samad CTO
 Chief Tech/Sci/R&D Officer - 2021-04-30
Manager TitleAgeSince
Lars Søren Rasmussen CHM
 Chairman 65 2016-03-30
Lene Skole-Sørensen BRD
 Director/Board Member 65 2015-03-24
Lars Erik Holmqvist BRD
 Director/Board Member 65 2015-03-24
More insiders

ETFs: H. Lundbeck A/S

Name Weight AuM 1st Jan change Investor Rating
FIRST TRUST IPOX EUROPE EQUITY OPPORTUNITIES ETF - DISTRIBUTING - USD ETF First Trust IPOX Europe Equity Opportunities ETF - Distributing - USD
0.25% 4 M€ +19.46%
SIMPLIFY DEVELOPED EX-US PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Developed Ex-US Plus Downside Convexity ETF - USD
0.01% 10 M€ -3.35% -
More ETFs: H. Lundbeck A/S

Pharmaceuticals Wholesale

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
H. LUNDBECK A/S Stock H. Lundbeck A/S
+0.09%-2.83%+34.56% - 5.96B
MCKESSON CORPORATION Stock McKesson Corporation
+0.34%+0.85%+33.56%+189.95%79.78B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-0.32%+0.33%+14.16%+164.42%29.58B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
-0.32%+0.23%+21.10%+18.21%9.9B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
+6.79%+11.02%-4.44%+15.02%9.42B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+1.00%+1.25%+4.75%+19.83%8.14B
EBOS GROUP LIMITED Stock EBOS Group Limited
-.--%+1.33%+2.70%+4.25%4.37B
GALENICA AG Stock Galenica AG
-0.07%-0.65%+5.51%+21.47%4.33B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+1.70%+2.68%-7.76%+5.71%3.64B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+0.09%-2.26%+11.98%+10.78%3.56B
Average +0.93%+1.62%+11.61%+49.96% 15.87B
Weighted average by Cap. +0.59%+1.53%+22.42%+135.35%
See all sector performances

Financials

2024 *2025 *
Net sales 22.05B 3.12B 2.96B 2.75B 2.46B 4.37B 264B 4.79B 34.08B 12.69B 108B 11.73B 11.46B 470B 23.34B 3.3B 3.13B 2.91B 2.6B 4.63B 279B 5.07B 36.06B 13.43B 115B 12.41B 12.13B 497B
Net income 3.04B 430M 408M 379M 339M 603M 36.38B 660M 4.7B 1.75B 14.92B 1.62B 1.58B 64.74B 3.58B 507M 480M 447M 399M 710M 42.86B 778M 5.53B 2.06B 17.58B 1.9B 1.86B 76.27B
Net Debt 6.33B 895M 849M 790M 705M 1.25B 75.73B 1.37B 9.78B 3.64B 31.07B 3.36B 3.29B 135B 2.53B 358M 339M 315M 281M 501M 30.24B 549M 3.9B 1.45B 12.4B 1.34B 1.31B 53.81B
More financial data * Estimated data

Company Profile

Logo H. Lundbeck A/S
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,500
Sector
Pharmaceuticals
Calendar
2025-02-04 - Q4 2024 Earnings Release
More about the company

Quotes

Date Price Change Volume
24-11-29 44.00 kr +0.09% 955,239
24-11-28 43.96 kr -0.54% 209,196
24-11-27 44.20 kr +0.68% 229,352
24-11-26 43.90 kr -2.23% 370,352
24-11-25 44.90 kr -0.84% 562,268

Delayed Quote Nasdaq Copenhagen, November 29, 2024 at 11:20 am EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart H-LUNDBECK-A-S More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
B-
surperformance-ratings-light-chart H-LUNDBECK-A-SMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
44.00DKK
Average target price
50.14DKK
Spread / Average Target
+13.95%
Consensus
Profit revisions
estimates-change-chart H-LUNDBECK-A-S Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart H-LUNDBECK-A-S Company calendar
  1. Stock Market
  2. Equities
  3. HLUN B Stock
LAST HOURS | BLACK FRIDAY -40%: Unlock Tomorrow's Top Investments with Our Exclusive Subscriber-Only Tools!
d
:
:
BENEFIT NOW